C25.0
Conditions
Interventions
Group 1: Patients with histologically confirmed pancreatic cancer.
Blood sampling during routine laboratory checks at the time of diagnosis or before starting therapy (operation vs. chemotherapy), an
Sponsors
Uniklinik Köln
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: - = 18 years, male or female - Patients with a confirmed diagnosis of pancreatic cancer (ICD-10, C25) - Healthy controls: no known malignancy, no permanent medication, normal weight (BMI 18.5 - 24.9). - Present declaration of consent
Exclusion criteria
Exclusion criteria: - Non-compliance with inclusion criteria - other malignancy - known autoimmune disease - Indications that the subject is unlikely to comply with the test plan (e.g. lack of willingness to cooperate)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detection of potential biomarker in pancreatic cancer. Blood sampling during routine laboratory checks at the time of diagnosis or before starting therapy (operation vs. chemotherapy), and also every 3 months during staging examinations. | — |
Secondary
| Measure | Time frame |
|---|---|
| prognostic relevance, analysis of chemoresistance. | — |
Countries
Germany
Contacts
Public ContactDilan Elcin Gülcicegi
Uniklinik Köln Klinik für Gastroenterologie
Outcome results
None listed